Cartilage oligomeric matrix protein in patients with osteoarthritis is independently associated with metastatic disease in prostate cancer.

Cartilage oligomeric matrix protein in patients with osteoarthritis is independently associated with metastatic disease in prostate cancer.
复制标题

DOI:
10.18632/oncotarget.27113
复制
发表时间:
2019-07-30
期刊:
影响因子:
--
通讯作者:
Willey, Jeffrey S
Willey, Jeffrey S
中科院分区:
其他
文献类型:
--
作者:
Rosas, Samuel;Hughes, Ryan T;Willey, Jeffrey S

文献摘要

被引文献

相似文献

转移性前列腺癌的5年生存率为30%。确定转移结果的预测因子可能会降低患者的死亡率。本研究的目的是确定骨关节炎是否对前列腺癌的结局有影响,包括死亡、局部复发和/或转移,并确定是否涉及软骨寡聚基质蛋白。我们对诊断为和未诊断为骨关节炎的前列腺癌患者进行了回顾性病例对照研究,并完成了前列腺(n=20)和淋巴结(n=7)手术标本的免疫组织化学(IHC)分析。我们通过各种IHC生物标志物,包括前列腺特异性膜抗原(PSMA)、软骨寡聚基质蛋白(COMP)、CD 31和Ki-67,评估了死亡、局部复发和转移性疾病。我们的模型将骨关节炎确定为转移性疾病的独立风险因素(OR 5.24,95%CI 1.49 - 18.41)。最值得注意的是,当模型中包括关节置换术时,骨关节炎不再是该结局的独立风险因素(p=0.071)。免疫组化显示,骨关节炎患者的前列腺样本中COMP表达更高(平均23.9% vs 5.84%,p
Metastatic prostate cancer has a 5-year survival rate of 30%. Identifying predictors of metastasis outcome could potentially reduce patient mortality. The objective of this study was to determine whether osteoarthritis had an impact on outcomes of prostate cancer including death, local recurrence and/or metastasis and to determine whether cartilage oligomeric matrix protein was involved. We performed a retrospective case-control study of patients with prostate cancer with and without the diagnosis of osteoarthritis and completed immunohistochemistry (IHC) analysis of prostate (n=20) and lymph node (n=7) surgical specimens. We evaluated death, local recurrence and metastatic disease by various IHC biomarkers including prostate specific membrane antigen (PSMA), cartilage oligomeric matrix protein (COMP), CD31, and Ki-67. Our model identified osteoarthritis as an independent risk factor for metastatic disease (OR 5.24, 95% CI 1.49 - 18.41). Most notably, when joint arthroplasty was included in the model, osteoarthritis was no longer an independent risk factor for this outcome (p=0.071). IHC demonstrated that those with osteoarthritis, had greater expression of COMP in the prostate samples (mean 23.9% vs 5.84%, p